Predictors of vibration perception threshold in type 2 diabetic patients with proliferative retinopathy

Postgraduate Medical Journal

Volumn 87, Issue 1032, 2011, Pages 658-663

  Magri, Caroline Jane ^a,b   Calleja, Neville ^c   Buhagiar, Gerald ^a   Fava, Stephen ^a,b   Vassallo, Josanne ^a,b  

^a MATER DEI HOSPITAL   (Malta)

^b UNIVERSITY OF MALTA MEDICAL SCHOOL   (Malta)

^c Department of Health Information and Research ^*  (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; URIC ACID;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; DISTAL PERIPHERAL RETINOPATHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTIVE THRESHOLD; PREVALENCE; QUESTIONNAIRE; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; URINALYSIS; VIBRATION PERCEPTION THRESHOLD;

AGE FACTORS; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROLOGIC EXAMINATION; PERCEPTION; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; RISK FACTORS; SENSORY THRESHOLDS; SEX FACTORS; VIBRATION;

EID: 80053367780     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2010.104216     Document Type: Article

References (43)

1. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality of issues. Mayo Clin Proc 2006;81:S3-11.
2. Cusick M. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes. Diabetes Care 2005;28:617-25.
3. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. JAMA 2003;290:1371-6.
4. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53. Erratum in: Lancet 1999 Aug 14; 354(9178):602.
6. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, et al. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol 2001;24:1-11.
7. Nasseri K, Strijers RL, Dekhuijzen LS, et al. Reproducibility of different methods for diagnosing and monitoring diabetic neuropathy. Electromyogr Clin Neurophysiol 1998;38:295-9.
8. Mythili A, Kumar KD, Subrahmanyam KA, et al. A Comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy. Int J Diabetes Dev Ctries 2010;30:43-8.
9. Young MJ, Breddy L, Veves A, et al. The prediction of diabetic neuropathic foot ulceration using vibratory perception thresholds. Diabetes Care 1994;17:557-60.
10. Elliott J, Tesfaye S, Chaturvedi N, et al. EURODIAB Prospective Complications Study Group: Large-fibre dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009;32:1896-900.
11. Kärvestedt L, Mårtensson E, Grill V, et al. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 2009;32:317-22.
12. Klein S, Hage JJ. Measurement, calculation, and normal range of the Ankle-Arm Index: a bibliometric analysis and recommendation for standardization. Ann Vasc Surg 2006;20:282-92.
13. Papanas N, Symeonidis G, Mavridis G, et al. Ankle-brachial index: a surrogate marker of microvascular complications in type 2 diabetes mellitus? Int Angiol 2007;26:253-7.
14. National Kidney Foundation. Calculator for Healthcare Professsionals. http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm.
15. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Concensus Group. The metabolic syndrome- a new worldwide definition. Lancet 2005;366:1059-62.
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and b cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
17. National Collaborating Centre for Chronic Conditions. Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: Royal College of Physicians, 2008.
18. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31.
19. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007;27:1189-97.
20. Craig KJ, Williams JD, Riley SG, et al. Anemia and diabetes in the absence of nephropathy. Diabetes Care 2005;28:1118-23.
21. Thomas MC, Tsalamandris C, MacIsaac RJ, et al. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis 2006;48:537-45.
22. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010;33:156-61.
23. Kabakus N, Ayar A, Yoldas TK, et al. Reversal of iron deficiency anemia-induced peripheral neuropathy by iron treatment in children with iron deficiency anemia. J Trop Pediatr 2002;48:204-9.
24. Madsen PL, Scheuermann Freestone M, Neubauer S, et al. Haemoglobin and flow-mediated vasodilation. Clin Sci (Lond) 2006;110:467-73.
25. Sonmez A, Yilmaz MI, Saglam M, et al. The relationship between hemoglobin levels and endothelial functions in diabetes mellitus. Clin J Am Soc Nephrol 2009;5:45-50.
26. Grubina R, Huang Z, Shiva S, et al. Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy- and oxyhemoglobin. J Biol Chem. 2007;282:12916-27.
27. Allen BW, Piantadosi CA. How do red blood cells cause hypoxic vasodilation? The SNO-hemoglobin paradigm, Am J Physiol Heart Circ Physiol 2006;291:H1507-12.
28. Huang Z, Shiva S, Kim-Shapiro DB, et al. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest 2005;115:2099-107.
29. Veves A, Donaghue VM, Sarnow MR, et al. The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Diabetologia 1996;39:344-8.
30. Dunst J, Becker A, Lautenschläger C, et al. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 2002;178:436-4.
31. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001;107:1083-92.
32. Thomas MC. The high prevalence of anaemia in diabetes is linked to functional erythropoietin deficiency. Semin Nephrol 2006;26:275-82.
33. Cotroneo P, Maria Ricerca B, Todaro L, et al. Blunted erythropoietin response to anemia in patients with type 1 diabetes. Diabetes Metab Res Rev 2000;16:172-6.
34. Schmidt RE, Green KG, Feng D, et al. Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 2008;209:161-70.
35. Yin ZS, Zhang H, Bo W, et al. Erythropoietin promotes functional recovery and enhances nerve regeneration after peripheral nerve injury in rats. AJNR Am J Neuroradiol 2010;31:509-15.
36. Bianchi R, Gilardini A, Rodriguez-Menendez V, et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 2007;43:710-17.
37. Yoon MS, Bechmann L, Obermann M. Recombinant human erythropoietin counteracts cisplatin-induced visceral hyperalgesia. Neurosci Bull 2010;26:282-8.
38. Kassem LA, Yassin NA. Role of erythropoietin in prevention of chemotherapy-induced peripheral neuropathy. Pak J Biol Sci 2010;13:577-87.
39. Hassan K, Simri W, Rubenchik I, et al. Effect of erythropoietin therapy on polyneuropathy in predialytic patients. J Nephrol 2003;16:121-5.
40. Keswani SC, Leitz GJ, Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett 2004;371:102-5.
41. Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythropoietin recaptor and nitric oxide production by endothelial cells. Blood 2004;104:2073-80.
42. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
43. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990;87:5978-82.